All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Is a TP53 mutation always a poor prognostic marker for transplantation in AML?
During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke to Justin Loke, University of Birmingham, Birmingham, UK. We asked, Is a TP53 mutation always a poor prognostic marker for transplantation in AML?
Is a TP53 mutation always a poor prognostic marker for transplantation in AML?
Historically, patients with TP53 mutations have been known to have adverse prognostic features even after intensive chemotherapy treatment, rendering the option of allogeneic transplantation of little value to the patient. In this video, Loke reviews transplant variables and other prognostic factors affecting the outcomes of patients with TP53-AML who have undergone allogeneic transplant.
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox